{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T21:31:12Z","timestamp":1793223072274,"version":"4.5.0"},"reference-count":50,"publisher":"American Medical Association (AMA)","issue":"12","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Oncol"],"published-print":{"date-parts":[[2025,12,1]]},"abstract":"\n Importance<\/jats:title>\n Hormonal contraceptives are widely used but how breast cancer risk differs by hormonal content remains unclear.<\/jats:p>\n <\/jats:sec>\n \n Objective<\/jats:title>\n To estimate the difference in breast cancer risk associated with different hormonal contraceptive formulations.<\/jats:p>\n <\/jats:sec>\n \n Design, Setting, and Participants<\/jats:title>\n This Swedish nationwide, population-based cohort study was conducted using linked national registers. All adolescent girls and women aged 13 to 49 years residing in Sweden as of January 1, 2006, with no history of breast cancer, ovarian cancer, cervical cancer, uterine cancer, bilateral oophorectomy, or infertility treatment were included and followed up from 2006 to 2019. Individuals were censored on meeting an exclusion criterion, reaching age 50 years, or study end, whichever occurred first. Data were analyzed from November 2023 to August 2025.<\/jats:p>\n <\/jats:sec>\n \n Exposure<\/jats:title>\n Ever use and duration of use of hormonal contraceptives, categorized by hormone formulations and route of administration.<\/jats:p>\n <\/jats:sec>\n \n Main Outcomes and Measures<\/jats:title>\n Time-dependent Cox regression was used to estimate hazard ratios (HRs) with 95% CIs for incident cases of in situ and invasive breast cancer.<\/jats:p>\n <\/jats:sec>\n \n Results<\/jats:title>\n Among 2\u202f095\u202f130 adolescent girls and women (median [IQR] age at diagnosis, 45 [41-48] years) who were followed up for 21\u202f020\u202f846 person-years, 16\u202f385 breast cancer cases occurred. Ever use of any hormonal contraceptive was associated with increased breast cancer risk (HR, 1.24; 95% CI, 1.20-1.28), corresponding to 1 additional case per 7752 (95% CI, 5350-14\u202f070) users, with both combined (HR, 1.12; 95% CI, 1.07-1.17) and progestin-only formulations (HR, 1.21; 95% CI, 1.17-1.25) being associated. Higher risk was associated with oral desogestrel-only formulations (HR, 1.18; 95% CI, 1.13-1.23) and oral desogestrel-combined formulations (HR, 1.19; 95% CI, 1.08-1.31), as well as implants containing etonogestrel, desogestrel\u2019s active metabolite (HR, 1.22; 95% CI, 1.11-1.35), compared to levonorgestrel-containing combined pills (HR, 1.09; 95% CI, 1.03-1.15) and levonorgestrel, 52 mg, intrauterine system (HR, 1.13; 95% CI, 1.09-1.18). No statistically significant increased risk was observed for medroxyprogesterone acetate injection, etonogestrel vaginal ring, or combined oral drospirenone, despite having many users.<\/jats:p>\n <\/jats:sec>\n \n Conclusions and Relevance<\/jats:title>\n Findings of this cohort study highlight that breast cancer risk varies substantially by progestin content in hormonal contraceptives, providing valuable insights to support more informed contraceptive prescription.<\/jats:p>\n <\/jats:sec>","DOI":"10.1001\/jamaoncol.2025.4480","type":"journal-article","created":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T15:31:38Z","timestamp":1761838298000},"page":"1497","source":"Crossref","is-referenced-by-count":22,"title":["Hormonal Contraceptive Formulations and Breast Cancer Risk in Adolescents and Premenopausal Women"],"prefix":"10.1001","volume":"11","author":[{"given":"Fatemeh","family":"Hadizadeh","sequence":"first","affiliation":[{"name":"Department of Immunology, Genetics and Pathology, SciLifeLab, Uppsala University, Uppsala, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ardita","family":"Koteci","sequence":"additional","affiliation":[{"name":"Department of Immunology, Genetics and Pathology, SciLifeLab, Uppsala University, Uppsala, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Torgny","family":"Karlsson","sequence":"additional","affiliation":[{"name":"Department of Immunology, Genetics and Pathology, SciLifeLab, Uppsala University, Uppsala, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weronica E.","family":"Ek","sequence":"additional","affiliation":[{"name":"Department of Immunology, Genetics and Pathology, SciLifeLab, Uppsala University, Uppsala, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"\u00c5sa","family":"Johansson","sequence":"additional","affiliation":[{"name":"Department of Immunology, Genetics and Pathology, SciLifeLab, Uppsala University, Uppsala, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","reference":[{"issue":"8","key":"coi250066r1","doi-asserted-by":"publisher","first-page":"e583","DOI":"10.1016\/S2468-2667(24)00156-7","article-title":"Differences in cancer rates among adults born between 1920 and 1990 in the USA: an analysis of population-based cancer registry data.","volume":"9","author":"Sung","year":"2024","journal-title":"Lancet Public Health"},{"issue":"1","key":"coi250066r2","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2023.53331","article-title":"Breast cancer incidence among US women aged 20 to 49 years by race, stage, and hormone receptor status.","volume":"7","author":"Xu","year":"2024","journal-title":"JAMA Netw Open"},{"issue":"10","key":"coi250066r3","doi-asserted-by":"publisher","first-page":"1374","DOI":"10.1038\/s41416-022-01704-x","article-title":"Incidence trends for twelve cancers in younger adults-a rapid review.","volume":"126","author":"di Martino","year":"2022","journal-title":"Br J Cancer"},{"issue":"8","key":"coi250066r4","doi-asserted-by":"publisher","first-page":"e1027","DOI":"10.1016\/S2214-109X(20)30215-1","article-title":"Global burden and trends in premenopausal and postmenopausal breast cancer: a population-based study.","volume":"8","author":"Heer","year":"2020","journal-title":"Lancet Glob Health"},{"issue":"1","key":"coi250066r5","first-page":"10","article-title":"Cancer statistics, 2025.","volume":"75","author":"Siegel","year":"2025","journal-title":"CA Cancer J Clin"},{"key":"coi250066r6","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1016\/j.breast.2022.08.010","article-title":"Current and future burden of breast cancer: global statistics for 2020 and 2040.","volume":"66","author":"Arnold","year":"2022","journal-title":"Breast"},{"key":"coi250066r7","doi-asserted-by":"publisher","first-page":"227","DOI":"10.2147\/BCTT.S390664","article-title":"Re-evaluating the association between hormonal contraception and breast cancer risk.","volume":"15","author":"Satish","year":"2023","journal-title":"Breast Cancer (Dove Med Press)"},{"issue":"7967","key":"coi250066r9","doi-asserted-by":"publisher","first-page":"1024","DOI":"10.1038\/s41586-023-06057-w","article-title":"ERa-associated translocations underlie oncogene amplifications in breast cancer.","volume":"618","author":"Lee","year":"2023","journal-title":"Nature"},{"issue":"1","key":"coi250066r10","doi-asserted-by":"publisher","first-page":"T49","DOI":"10.1530\/JME-20-0104","article-title":"90 years of progesterone: progesterone and progesterone receptors in breast cancer: past, present, future.","volume":"65","author":"Horwitz","year":"2020","journal-title":"J Mol Endocrinol"},{"issue":"3","key":"coi250066r11","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1590\/1414-431x20175612","article-title":"Estrogen and progesterone promote breast cancer cell proliferation by inducing cyclin G1 expression.","volume":"51","author":"Tian","year":"2018","journal-title":"Braz J Med Biol Res"},{"issue":"7","key":"coi250066r12","doi-asserted-by":"publisher","DOI":"10.15252\/emmm.202114314","article-title":"Contraceptive progestins with androgenic properties stimulate breast epithelial cell proliferation.","volume":"13","author":"Shamseddin","year":"2021","journal-title":"EMBO Mol Med"},{"key":"coi250066r13","doi-asserted-by":"publisher","first-page":"798","DOI":"10.1016\/j.jconrel.2022.03.057","article-title":"Non-oral routes, novel formulations and devices of contraceptives: an update.","volume":"345","author":"Gupta","year":"2022","journal-title":"J Control Release"},{"issue":"9017","key":"coi250066r14","doi-asserted-by":"publisher","first-page":"1713","DOI":"10.1016\/S0140-6736(96)90806-5","article-title":"Breast cancer and hormonal contraceptives: collaborative reanalysis of individual data on 53?297 women with breast cancer and 100?239 women without breast cancer from 54 epidemiological studies.","volume":"347","author":"Collaborative Group on Hormonal Factors in Breast Cancer","year":"1996","journal-title":"Lancet"},{"issue":"10","key":"coi250066r15","doi-asserted-by":"publisher","first-page":"2496","DOI":"10.1158\/1055-9965.EPI-10-0747","article-title":"Oral contraceptive use and breast cancer: a prospective study of young women.","volume":"19","author":"Hunter","year":"2010","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"issue":"6","key":"coi250066r16","doi-asserted-by":"publisher","first-page":"821.e1","DOI":"10.1016\/j.ajog.2021.12.022","article-title":"Oral contraceptive use by formulation and breast cancer risk by subtype in the Nurses\u2019 Health Study II: a prospective cohort study.","volume":"226","author":"Burchardt","year":"2022","journal-title":"Am J Obstet Gynecol"},{"issue":"26","key":"coi250066r17","doi-asserted-by":"publisher","first-page":"2025","DOI":"10.1056\/NEJMoa013202","article-title":"Oral contraceptives and the risk of breast cancer.","volume":"346","author":"Marchbanks","year":"2002","journal-title":"N Engl J Med"},{"issue":"23","key":"coi250066r18","doi-asserted-by":"publisher","first-page":"2228","DOI":"10.1056\/NEJMoa1700732","article-title":"Contemporary hormonal contraception and the risk of breast cancer.","volume":"377","author":"M\u00f8rch","year":"2017","journal-title":"N Engl J Med"},{"issue":"3","key":"coi250066r19","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.1004188","article-title":"Combined and progestagen-only hormonal contraceptives and breast cancer risk: a UK nested case-control study and meta-analysis.","volume":"20","author":"Fitzpatrick","year":"2023","journal-title":"PLoS Med"},{"key":"coi250066r20","doi-asserted-by":"publisher","DOI":"10.1016\/j.lanepe.2022.100470","article-title":"Hormonal contraception and risk of breast cancer and breast cancer in situ among Swedish women 15-34 years of age: a nationwide register-based study.","volume":"21","author":"Niemeyer Hultstrand","year":"2022","journal-title":"Lancet Reg Health Eur"},{"issue":"4","key":"coi250066r21","doi-asserted-by":"publisher","first-page":"450.e1","DOI":"10.1016\/j.ajog.2024.05.011","article-title":"Association of levonorgestrel-releasing intrauterine device with gynecologic and breast cancers: a national cohort study in Sweden.","volume":"231","author":"Yi","year":"2024","journal-title":"Am J Obstet Gynecol"},{"issue":"5","key":"coi250066r22","doi-asserted-by":"publisher","first-page":"1046","DOI":"10.1093\/jnci\/djae282","article-title":"Long-acting, progestin-based contraceptives and risk of breast, gynecological, and other cancers.","volume":"117","author":"Tuesley","year":"2025","journal-title":"J Natl Cancer Inst"},{"issue":"18","key":"coi250066r23","doi-asserted-by":"publisher","first-page":"1578","DOI":"10.1001\/jama.2024.18575","article-title":"Breast cancer in users of levonorgestrel-releasing intrauterine systems.","volume":"332","author":"M\u00f8rch","year":"2024","journal-title":"JAMA"},{"issue":"5","key":"coi250066r24","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1097\/AOG.0000000000005881","article-title":"Association between levonorgestrel-releasing intrauterine system exposure duration and breast cancer incidence.","volume":"145","author":"Yuk","year":"2025","journal-title":"Obstet Gynecol"},{"key":"coi250066r25","doi-asserted-by":"publisher","first-page":"S59","DOI":"10.1016\/j.maturitas.2003.09.020","article-title":"Progestins and their effects on the breast.","volume":"46","author":"Druckmann","year":"2003","journal-title":"Maturitas"},{"issue":"2","key":"coi250066r26","doi-asserted-by":"publisher","first-page":"320","DOI":"10.1210\/endrev\/bnz001","article-title":"Progesterone and breast cancer.","volume":"41","author":"Trabert","year":"2020","journal-title":"Endocr Rev"},{"issue":"1","key":"coi250066r27","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1186\/s13643-016-0294-5","article-title":"Progesterone vs. synthetic progestins and the risk of breast cancer: a systematic review and meta-analysis.","volume":"5","author":"Asi","year":"2016","journal-title":"Syst Rev"},{"issue":"8","key":"coi250066r29","doi-asserted-by":"publisher","first-page":"2101","DOI":"10.1093\/rheumatology\/kead513","article-title":"Effects of oral contraceptives and menopausal hormone therapy on the risk of rheumatoid arthritis: a prospective cohort study.","volume":"63","author":"Hadizadeh","year":"2024","journal-title":"Rheumatology (Oxford)"},{"issue":"2","key":"coi250066r30","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1111\/tri.13081","article-title":"An unjustified benefit: immortal time bias in the analysis of time-dependent events.","volume":"31","author":"Gleiss","year":"2018","journal-title":"Transpl Int"},{"issue":"7","key":"coi250066r31","doi-asserted-by":"publisher","first-page":"686","DOI":"10.1001\/jama.2020.9151","article-title":"Immortal time bias in observational studies.","volume":"325","author":"Yadav","year":"2021","journal-title":"JAMA"},{"key":"coi250066r32","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1016\/j.jcrc.2016.07.017","article-title":"Immortal time bias in observational studies of time-to-event outcomes.","volume":"36","author":"Jones","year":"2016","journal-title":"J Crit Care"},{"issue":"3","key":"coi250066r33","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1016\/0010-7824(82)90078-6","article-title":"Serum levels and pharmacokinetics of norethisterone after ingestion of lynestrenol: its relation to dose and stage of the menstrual cycle.","volume":"26","author":"Kuhl","year":"1982","journal-title":"Contraception"},{"issue":"2","key":"coi250066r34","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1677\/joe.0.0470251","article-title":"Metabolism of lynestrenol to norethisterone by liver homogenate.","volume":"47","author":"Mazaheri","year":"1970","journal-title":"J Endocrinol"},{"issue":"1","key":"coi250066r35","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1016\/j.jclinepi.2009.03.012","article-title":"Absolute risk reductions and numbers needed to treat can be obtained from adjusted survival models for time-to-event outcomes.","volume":"63","author":"Austin","year":"2010","journal-title":"J Clin Epidemiol"},{"issue":"7","key":"coi250066r36","doi-asserted-by":"publisher","first-page":"120","DOI":"10.21037\/atm.2018.01.36","article-title":"Estimate risk difference and number needed to treat in survival analysis.","volume":"6","author":"Zhang","year":"2018","journal-title":"Ann Transl Med"},{"issue":"6","key":"coi250066r37","first-page":"337","article-title":"Etonogestrel (Implanon), another treatment option for contraception.","volume":"33","author":"Maddox","year":"2008","journal-title":"Pharm Ther"},{"issue":"1","key":"coi250066r38","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1517\/17425255.2013.844229","article-title":"Pharmacokinetic evaluation of desogestrel as a female contraceptive.","volume":"10","author":"Grandi","year":"2014","journal-title":"Expert Opin Drug Metab Toxicol"},{"issue":"3","key":"coi250066r39","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1016\/j.contraception.2011.12.015","article-title":"Lowering oral contraceptive norethindrone dose increases estrogen and progesterone receptor levels with no reduction in proliferation of breast epithelium: a randomized trial.","volume":"86","author":"Hovanessian-Larsen","year":"2012","journal-title":"Contraception"},{"key":"coi250066r40","doi-asserted-by":"publisher","DOI":"10.1016\/j.jsbmb.2023.106440","article-title":"Progestins and breast cancer hallmarks: the role of the ERK1\/2 and JNK pathways in estrogen receptor positive breast cancer cells.","volume":"237","author":"Louw-du Toit","year":"2024","journal-title":"J Steroid Biochem Mol Biol"},{"issue":"3","key":"coi250066r41","doi-asserted-by":"publisher","first-page":"374","DOI":"10.1210\/er.2003-0016","article-title":"Testosterone effects on the breast: implications for testosterone therapy for women.","volume":"25","author":"Somboonporn","year":"2004","journal-title":"Endocr Rev"},{"issue":"3","key":"coi250066r42","doi-asserted-by":"publisher","first-page":"R257","DOI":"10.1530\/JME-14-0030","article-title":"Revising the role of the androgen receptor in breast cancer.","volume":"52","author":"Fioretti","year":"2014","journal-title":"J Mol Endocrinol"},{"issue":"1-2","key":"coi250066r43","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1016\/S0303-7207(99)00109-4","article-title":"Androgen receptor agonist activity of the synthetic progestin, medroxyprogesterone acetate, in human breast cancer cells.","volume":"154","author":"Bentel","year":"1999","journal-title":"Mol Cell Endocrinol"},{"issue":"10-11","key":"coi250066r44","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1016\/S0039-128X(00)00119-7","article-title":"Nestorone: a progestin with a unique pharmacological profile.","volume":"65","author":"Kumar","year":"2000","journal-title":"Steroids"},{"issue":"18","key":"coi250066r45","doi-asserted-by":"publisher","first-page":"30142","DOI":"10.1016\/j.contraception.2018.04.006","article-title":"Twelve-month discontinuation rates of levonorgestrel intrauterine system 13.5 mg and subdermal etonogestrel implant in women aged 18-44: A retrospective claims database analysis.","volume":"S0010-7824","author":"Law","year":"2018","journal-title":"Contraception"},{"issue":"1","key":"coi250066r46","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1186\/s12905-022-01657-6","article-title":"Discontinuation rates of intrauterine contraception due to unfavourable bleeding: a systematic review.","volume":"22","author":"Costescu","year":"2022","journal-title":"BMC Womens Health"},{"issue":"5","key":"coi250066r47","doi-asserted-by":"publisher","first-page":"1105","DOI":"10.1097\/AOG.0b013e31821188ad","article-title":"Continuation and satisfaction of reversible contraception.","volume":"117","author":"Peipert","year":"2011","journal-title":"Obstet Gynecol"},{"issue":"4","key":"coi250066r48","doi-asserted-by":"publisher","first-page":"e626","DOI":"10.1016\/S2214-109X(24)00560-6","article-title":"Global and regional causes of maternal deaths 2009-20: a WHO systematic analysis.","volume":"13","author":"Cresswell","year":"2025","journal-title":"Lancet Glob Health"},{"key":"coi250066r49","doi-asserted-by":"publisher","first-page":"k3609","DOI":"10.1136\/bmj.k3609","article-title":"Association between contemporary hormonal contraception and ovarian cancer in women of reproductive age in Denmark: prospective, nationwide cohort study.","volume":"362","author":"Iversen","year":"2018","journal-title":"BMJ"},{"issue":"3","key":"coi250066r50","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1016\/j.contraception.2020.06.008","article-title":"Contemporary hormonal contraception and risk of endometrial cancer in women younger than age 50: a retrospective cohort study of Danish women.","volume":"102","author":"Iversen","year":"2020","journal-title":"Contraception"},{"key":"coi250066r28","volume-title":"Combined Estrogen-Progestogen Contraceptives and Combined Estrogen-Progestogen Menopausal Therapy","year":"2007"},{"key":"coi250066r8","unstructured":"World Family Planning 2022: meeting the changing needs for family planning: contraceptive use by age and method. United Nations. December 23, 2022. Accessed January 31, 2025. https:\/\/desapublications.un.org\/publications\/world-family-planning-2022-meeting-changing-needs-family-planning-contraceptive-use"}],"container-title":["JAMA Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamaoncology\/articlepdf\/2840506\/jamaoncology_hadizadeh_2025_oi_250066_1765564170.65132.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,18]],"date-time":"2025-12-18T16:00:53Z","timestamp":1766073653000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamaoncology\/fullarticle\/2840506"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,1]]},"references-count":50,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2025,12,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamaoncol.2025.4480","relation":{},"ISSN":["2374-2437"],"issn-type":[{"value":"2374-2437","type":"print"}],"subject":[],"published":{"date-parts":[[2025,12,1]]}}}